Aquestive Therapeutics Inc (AQST):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aquestive Therapeutics Inc (AQST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3035
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aquestive Therapeutics Inc (Aquestive Therapeutics) is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm a drug delivery platform that delivers existing prescription products directly to the bloodstream. Its products include suboxone, rizatriptan, zuplenz, clobazam, diazepam, meloxicam, colchicine, flu vaccine, and others. Aquestive Therapeutics also provides nutraceutical products, packaging solutions, consumer products, and drug products for the treatment of nausea, opioid dependence, and vomiting. The company partners with other pharmaceutical companies for the development and commercialization of pharmaceutical products. It has its operations in New Jersey and Indiana, the US. Aquestive Therapeutics is headquartered in Warren, New Jersey, the US.

Aquestive Therapeutics Inc (AQST) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aquestive Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Monosol Acquires Buccal Film Patent From Fuisz Pharma 12
Venture Financing 13
Aquestive Therapeutics Raises USD9.1 Million in Venture Financing 13
Partnerships 14
Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 14
Midatech Enters Into Joint Venture With MonoSol Rx 16
Licensing Agreements 17
Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 17
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 18
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 19
Monosol Rx Enters Into Licensing Agreement With Vestiq Pharma For Zuplenz 20
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 21
Equity Offering 22
Aquestive Therapeutics Completes Underwriters Exercise of Over-Allotment Option of IPO of Shares of Shares for USD73.9 Million 22
Aquestive Therapeutics Inc – Key Competitors 24
Aquestive Therapeutics Inc – Key Employees 25
Aquestive Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Joint Venture 26
Recent Developments 27
Corporate Communications 27
May 02, 2018: Aquestive Therapeutics Appoints Nancy Lurker to Board of Directors 27
Apr 11, 2017: MonoSol Rx Appoints James S. Scibetta to Board of Directors 28
Jan 24, 2017: MonoSol Rx Appoints John T. Maxwell as Chief Financial Officer 29
Product News 30
01/18/2018: Aquestive Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Clobazam Oral Soluble Film to Treat Lennox-Gastaut Syndrome 30
01/06/2017: Monosol Rx Successfully Completes Dose Proportionality Study Of Diazepam Buccal Soluble Film To Treat Acute Repetitive Seizures 31
Product Approvals 32
Jan 31, 2018: Aquestive Therapeutics Receives U.S. FDA Orphan Drug Designation for Riluzole Oral Soluble Film to Treat ALS 32
Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm 33
Jan 04, 2017: MonoSol Rx Receives FDA Acceptance of Investigational New Drug Application for Riluzole Oral Soluble Film to Treat Amyotrophic Lateral Sclerosis 34
Clinical Trials 35
Jan 10, 2017: MonoSol Rx to Initiate Human Proof-of-Concept Study of Epinephrine Sublingual Soluble Film 35
Other Significant Developments 36
Nov 30, 2017: MonoSol Rx Changes Name to Aquestive Therapeutics and Expands CNS Product Portfolio 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aquestive Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aquestive Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Monosol Acquires Buccal Film Patent From Fuisz Pharma 12
Aquestive Therapeutics Raises USD9.1 Million in Venture Financing 13
Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 14
Midatech Enters Into Joint Venture With MonoSol Rx 16
Aquestive Therapeutics Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 17
Cynapsus Therapeutics Enters into Licensing Agreement with MonoSol Rx 18
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 19
Monosol Rx Enters Into Licensing Agreement With Vestiq Pharma For Zuplenz 20
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 21
Aquestive Therapeutics Completes Underwriters Exercise of Over-Allotment Option of IPO of Shares of Shares for USD73.9 Million 22
Aquestive Therapeutics Inc, Key Competitors 24
Aquestive Therapeutics Inc, Key Employees 25
Aquestive Therapeutics Inc, Other Locations 26
Aquestive Therapeutics Inc, Joint Venture 26

List of Figures
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aquestive Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aquestive Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Aquestive Therapeutics Inc (AQST):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mellors Catering Services:企業の戦略・SWOT・財務情報
    Mellors Catering Services - Strategy, SWOT and Corporate Finance Report Summary Mellors Catering Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CRH Medical Corp (CRH)-医療機器分野:企業M&A・提携分析
    Summary CRH Medical Corp (CRH Medical), formerly Medsurge Medical Products Corp is a medical device company that provides treatment of hemorrhoids. The company provides CRH O’Regan System, a hemorrhoid technology for treating hemorrhoid. It provides topical ointments and creams including preparation …
  • Mologic Ltd-医療機器分野:企業M&A・提携分析
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company’s products include bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit. Its experti …
  • Centene Corp (CNC)-製薬・医療分野:企業M&A・提携分析
    Summary Centene Corp (Centene) is a healthcare service provider that offers services to government sponsored healthcare programs with focus on under-insured and uninsured individuals. It provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts; and other health sol …
  • Indiana Resources Limited:企業の戦略・SWOT・財務分析
    Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Tat Seng Packaging Group Ltd. (T12):企業の戦略的SWOT分析
    Tat Seng Packaging Group Ltd. (T12) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Nexans SA (NEX)-エネルギー分野:企業M&A・提携分析
    Summary Nexans S.A. (Nexans) is a provider of cables and cabling solutions. The company offers copper and fiber-optic cables and cabling systems. It serves network operators, equipment and infrastructure manufacturers, and builders, installers and distributors in submarine and land, oil and gas, min …
  • Sino Oil and Gas Holdings Ltd (702):企業の財務・戦略的SWOT分析
    Summary Sino Oil and Gas Holdings Ltd (Sino Oil and Gas), formerly Genesis Energy Holdings Ltd, is an oil and gas company that offers production and development of oil properties. The company offers services such as oil and gas exploration, production, distribution, development and supplying service …
  • CellaVision AB (CEVI):企業の財務・戦略的SWOT分析
    CellaVision AB (CEVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Fuji Pharma Co Ltd (4554):企業の財務・戦略的SWOT分析
    Summary Fuji Pharma Co Ltd (Fuji Pharma) develops, manufactures, and commercializes pharmaceutical products. The company specializes in offering injection agents, drugs for external use, internal drugs, and diagnostic products among others. It also provides medical care products for women, acute med …
  • Orion Corp (ORNBV):製薬・医療:M&Aディール及び事業提携情報
    Summary Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous …
  • Handok Inc (002390)-医療機器分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • Smiths Group plc:企業の戦略・SWOT・財務情報
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • COWI AS:企業の戦略的SWOT分析
    COWI AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Immatics Biotechnologies GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs …
  • Sanochemia Pharmazeutika AG (SAC):企業の財務・戦略的SWOT分析
    Sanochemia Pharmazeutika AG (SAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Bank Alfalah Ltd:企業の戦略・SWOT・財務情報
    Bank Alfalah Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank Alfalah Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Daigas Group:企業の戦略・SWOT・財務分析
    Daigas Group - Strategy, SWOT and Corporate Finance Report Summary Daigas Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Lite-On Technology Corporation:企業の戦略・SWOT・財務情報
    Lite-On Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary Lite-On Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • ATGen Co Ltd (182400):製薬・医療:M&Aディール及び事業提携情報
    Summary ATGen Co Ltd (ATGen) is a manufacturer and supplier of proteins and monoclonal antibodies. The company offers neuroproteins, enzymes, heat shock proteins, ubiquitins, cancer related proteins, antibodies, viral antigens and hormones. It conducts research and development of medicines based on …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆